Financial PerformanceAbsci's cash & equivalents balance as of the end of 1Q25 was ~$135M, which management estimates provides a runway into 1H27.
PartnershipsManagement cited strong potential partnership interest for ABS-101, allowing for a collaboration independent of the TL1A bispecific that Absci is progressing through its early pipeline.
Technology And InnovationAbsci's AI-driven Antibody Design Model could help select antibody variants that are more human-like to mitigate potential downstream issues.